Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Purpose: The antibody–drug conjugate enfortumab vedotin (EV) releases a cytotoxic agent into tumor cells via binding to the membrane receptor NECTIN-4. EV was recently approved for patients with metastatic urothelial carcinoma (mUC) without prior assessment of the tumor receptor status as ubiquitous NECTIN-4 expression is assumed. Our objective was to determine the prevalence of membranous NECTIN-4 protein expression in primary tumors (PRIM) and patient-matched distant metastases (MET). Experimental Design: Membranous NECTIN-4 protein expression was measured (H-score) by IHC in PRIM and corresponding MET (N = 137) and in a multicenter EV-treated cohort (N = 47). Progression-free survival (PFS) after initiation of EV treatment was assessed for the NECTIN-4–negative/weak (H-score 0–99) versus moderate/strong (H-score 100–300) subgroup. The specificity of the NECTIN-4 IHC staining protocol was validated by establishing CRISPR-Cas9–induced polyclonal NECTIN-4 knockouts. Results: In our cohort, membranous NECTIN-4 expression significantly decreased during metastatic spread (Wilcoxon matched pairs P < 0.001; median H-score = 40; interquartile range, 0–140), with 39.4% of MET lacking membranous NECTIN-4 expression. In our multicenter EV cohort, absence or weak membranous NECTIN-4 expression (34.0% of the cohort) was associated with a significantly shortened PFS on EV (log-rank P < 0.001). Conclusions: Membranous NECTIN-4 expression is frequently decreased or absent in mUC tissue. Of note, the clinical benefit of EV strongly depends on membranous NECTIN-4 expression. Thus, our results are of highest clinical relevance and argue for a critical reconsideration of the current practice and suggest that the NECTIN-4 receptor status should be determined (ideally in a metastatic/progressive lesion) before initiation of EV. See related commentary by Aggen et al., p. 1377
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Genome engineering using the CRISPR-Cas9 system
Ran, F. A., Hsu, P. D., Wright, J., Agarwala, V., Scott, D. A., & Zhang, F. (2013) · Nature Protocols · doi:10.1038/nprot.2013.143 · Cited by 11,133
Antibody–drug conjugates for cancer therapy
Thomas, A., Teicher, B. A., & Hassan, R. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30030-4 · Cited by 606
Tagawa, S. T., Balar, A. V., Petrylak, D. P., Kalebasty, A. R., Loriot, Y., Fléchon, A., Jain, R. K., Agarwal, N., Bupathi, M., Barthelemy, P., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.03489 · Cited by 543
Cited by
Advances in diagnosis and treatment of bladder cancer
Lopez-Beltran, A., Cookson, M. S., Guercio, B. J., & Cheng, L. (2024) · BMJ · doi:10.1136/bmj-2023-076743 · Cited by 496
Exploring membranous NECTIN‐4 expression patterns and enfortumab vedotin response in prostate cancer
Weiten, R., Bernhardt, M., Niemann, M., Kristiansen, G., Grünwald, V., Ritter, M., Hölzel, M., Eckstein, M., Alajati, A., Klümper, N., et al. (2024) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.18572 · Cited by 12
Self-citation
Metadata
- Authors
- Klümper, N., Ralser, D. J., Ellinger, J., Roghmann, F., Albrecht, J., Below, E., Alajati, A., Sikic, D., Breyer, J., Bolenz, C., Zengerling, F., Erben, P., Schwamborn, K., Wirtz, R. M., Horn, T., Nagy, D., Toma, M., Kristiansen, G., Büttner, T., Hahn, O., Grünwald, V., Darr, C., Erne, E., Rausch, S., Bedke, J., Schlack, K., Abbas, M., Zschäbitz, S., Schwab, C., Mustea, A., Adam, P., Manseck, A., Wullich, B., Ritter, M., Hartmann, A., Gschwend, J., Weichert, W., Erlmeier, F., Hölzel, M., & Eckstein, M.
- Venue
- Clinical Cancer Research
- Published
- 2022-12-19
- Volume
- 29
- Issue
- 8
- Pages
- 1496-1505
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W4311928016
- Cited by
- 227
- References
- 3
- FWCI
- 36.88
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-22-1764
- The paper
- Klümper, N., Ralser, D. J., Ellinger, J., Roghmann, F., Albrecht, J., Below, E., Alajati, A., Sikic, D., Breyer, J., Bolenz, C., Zengerling, F., Erben, P., Schwamborn, K., Wirtz, R. M., Horn, T., Nagy, D., Toma, M., Kristiansen, G., Büttner, T., . . . Eckstein, M. (2023). Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-22-1764
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.